Compare Mesoblast Limited (MESO) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Starbucks Corp — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Starbucks Corp trades at $104.82 (market cap $119.45B). The key difference: Starbucks Corp is far larger — about 55× Mesoblast Limited's market cap, and Starbucks Corp pays a 2.37% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SBUX | |
|---|---|---|
Market Cap | $2.17B | $119.45B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $108.37 |
52-Week Low | $12.88 | $78.46 |
Enterprise Value | $2.17B | $142.14B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Starbucks (SBUX) trades at $104.64, down 0.81% on the day, with a bullish technical outlook supported by moving averages. The stock shows mixed earnings performance, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, while revenue growth remains steady. Recent news highlights cost-cutting initiatives, including a $400 million AI-driven software reduction plan, and strong channel development growth of 39% year-over-year in Q2 2026.
The investment outlook is cautiously optimistic, with a consensus price target of $108.86 offering modest upside. Key opportunities include margin expansion from cost efficiencies and dividend growth, but risks involve high valuation multiples, competitive pressures, and inconsistent earnings performance. Analyst sentiment is balanced with 47% buy and hold ratings each.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
